Related Experiment Video
Updated: Aug 5, 2026
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
PET Imaging of New Target PARP in Prostate Cancer
Zhao Yang1, Wei Wang2, Xuanyi Dai3
1Department of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for China, Tianjin 300060, China.
A new Gallium-68 labeled probe, [68Ga]Ga-FL9-7, effectively visualizes Poly (ADP-ribose) polymerase (PARP) in prostate cancer. This noninvasive imaging tool aids in tumor detection and monitoring PARP-inhibitor therapy response.
Area of Science:
- Nuclear medicine
- Molecular imaging
- Oncology
Background:
- Poly (ADP-ribose) polymerase (PARP) is overexpressed in prostate cancer, correlating with poor prognosis.
- PARP inhibitors are effective in HRD-positive tumors, but resistance develops in 30-70% of patients, often due to low PARP expression.
- Tissue biopsies have limitations for assessing PARP levels, necessitating noninvasive imaging methods.
Purpose of the Study:
- Develop a novel Gallium-68 ([68Ga]) labeled PARP-targeted radiotracer for prostate cancer visualization.
- Evaluate the potential of this radiotracer for monitoring PARP-targeted therapies.
- Lay the groundwork for PARP-targeted radionuclide therapy.
Main Methods:
- PET/CT imaging was performed in mice bearing 22RV1 prostate cancer xenografts.
- The [68Ga]Ga-FL9-7 probe was administered, with imaging at 1, 2, and 3 hours post-injection.
- Standardized uptake values (SUV) and tumor-to-normal tissue (T/NT) contrast ratios were calculated.
Main Results:
- [68Ga]Ga-FL9-7 showed rapid tumor accumulation, with optimal imaging contrast at 3 hours post-injection.
- Normal organ uptake (e.g., kidneys) peaked early and declined, while tumor uptake increased over time.
- The highest T/NT ratios were achieved at the 3-hour time point due to differential clearance.
Conclusions:
- The [68Ga]Ga-FL9-7 probe enables effective noninvasive visualization of PARP-1 expression in prostate cancer.
- This radiotracer has clinical potential for tumor localization and monitoring PARP-targeted therapies.
- The study supports further development of PARP-targeted radionuclide therapy strategies.
